Physician profile
Thomas David Perry
NPI 1821080300
$1,546.89
in general payments reported to CMS, 2019-2025
15 companies · $604 in 2025
The $604 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $616 · 2020: $27.50 · 2023: $138 · 2024: $161 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $903.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $515.86 | 2019-2025 | Repatha |
| Edwards Lifesciences Corporation | $160.81 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Impulse Dynamics (USA) INC. | $158.88 | 2025 | Optimizer |
| Inspire Medical Systems, INC. | $144.67 | 2025 | Inspire |
| Medtronic, INC. | $138.47 | 2023 | Intellis Adaptivestim |
| Boston Scientific Corporation | $111.50 | 2019 | |
| Allergan, INC. | $88.99 | 2019 | |
| Angiodynamics, INC. | $78.25 | 2025 | Auryon Laser System 100-120 Vac |
| Penumbra, INC. | $33.76 | 2025 | Indigo System |
| Amarin Pharma, INC. | $33.03 | 2019-2020 | |
| Aegerion Pharmaceuticals, INC. | $21.94 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $21.80 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.62 | 2019 | |
| Lilly USA, LLC | $12.50 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.